Multidisciplinary

Fremanezumab: Sustained benefits across the board for refractory migraine

Pearl Toh, 7 hours ago

After treatment with fremanezumab, a difficult-to-treat patient population with treatment-resistant episodic or chronic migraine saw sustained benefits across a broad range of measures, according to multiple analyses of the FOCUS study released during the AHS 2020 Virtual Meeting.

Use of FreeStyle Libre glucose monitoring system may reduce DKA

Roshini Claire Anthony, 11 hours ago

Use of the FreeStyle Libre glucose monitoring system almost halved the rates of hospitalization due to diabetic ketoacidosis (DKA), according to results of the retrospective RELIEF* study presented at ADA 2020.

P. mirifica gel useful for treating bacterial vaginosis but not genitourinary symptoms

11 hours ago

Use of 5% Pueraria mirifica vaginal gel in women with genitourinary syndrome of menopause effectively reduces indicators of bacterial vaginosis but does little to alleviate genitourinary symptoms, according to the results of a trial.

Left atrial appendage closure noninferior to DOACs in preventing AF-related CV, neurological events

12 hours ago

Percutaneous left atrial appendage closure (LAAC) is not inferior to direct oral anticoagulants (DOACs) in the prevention of major atrial fibrillation (AF)-related cardiovascular, neurological, and bleeding events, results of a recent study have shown.

COPD ups risk for all-cause mortality

Stephen Padilla, 13 hours ago

Patients with chronic obstructive pulmonary disease (COPD) are at significantly increased risk for all-cause mortality compared to those without COPD, with lung cancer and chronic lower airway disease being the leading causes of death in at-risk patients, particularly those aged <60 years, reveals a study.

Achieving full functional recovery in MDD: How do we get there?

29 Jun 2020

The Lundbeck Neuroscience Symposium was held at Sofitel KL Damansara over 2 days, with extensivediscussions on the management of various mental illness. On the first day, eminent local and internationalexperts weighed in on the treatment of major depressive disorder (MDD), including in the elderly and incases of coexisting anxiety.

Early Treatment Intensification in T2DM, The Time is Now

29 Jun 2020

At the Novartis-sponsored VERIFY Soft Launch held at Le Meridien, Kuala Lumpur, two distinguished speakers spoke on the latest updates in glucose-lowering therapy and the benefit of early treatment intensification using combination therapy (ie, vildagliptin/metformin) in the management of T2DM.

HK in CKD: Do diet, HD frequency matter?

Elvira Manzano, 28 Jun 2020

Hyperkalaemia (HK) occurrence and recurrence are frequent in advanced CKD*, creating a perfect storm for cardiovascular events and death, says Professor Juan-Jesus Carrero from the Karolinska Institute, Solna, Sweden, at ERA-EDTA 2020. Given these risks, acutely elevated potassium (K+) should merit clinical attention.

No increased ophthalmic risk with roxadustat treatment in DD CKD-related anaemia

Roshini Claire Anthony, 28 Jun 2020

Roxadustat treatment for anaemia in patients with dialysis-dependent chronic kidney disease (DD CKD) does not come with an increased risk of ophthalmic abnormalities, according to a phase III trial conducted in Japan.

JAVELIN: Paradigm shifts in maintenance for advanced bladder cancer

Pearl Toh, 02 Jul 2020

Adding the PD-L1 inhibitor avelumab to best supportive care in the maintenance setting yields significant survival benefit compared with best supporting care alone for patients with advanced bladder cancer who have stable disease following first-line platinum-based chemotherapy, an interim analysis of the JAVELIN Bladder 100 study shows.

Bexagliflozin puts BEST foot forward in T2D

Audrey Abella, 02 Jul 2020

The highly selective SGLT2 inhibitor bexagliflozin demonstrated significant efficacy and safety in controlling hyperglycaemia, weight, and blood pressure (BP) in patients with type 2 diabetes (T2D) who were at high risk of cardiovascular (CV) events, results of the BEST** trial have shown.

Pembrolizumab + chemo improves PFS in previously untreated, advanced TNBC

Christina Lau, 02 Jul 2020

Pembrolizumab in combination with chemotherapy significantly improves progression-free survival (PFS) vs chemotherapy alone in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), results of the KEYNOTE-355 study have shown.

Erenumab shows sustained efficacy in refractory migraine over 2 years

Pearl Toh, 01 Jul 2020

The CGRP* receptor blocker erenumab shows sustained efficacy in reducing migraine frequency over 2 years in a difficult-to-treat patient population with episodic migraine who had failed 2–4 prior preventive treatments, an interim analysis of the LIBERTY** open-label extension study shows.

Veliparib-carboplatin-paclitaxel combo improves PFS in HR+ or TNBC

Roshini Claire Anthony, 01 Jul 2020

Adding veliparib to a carboplatin-paclitaxel combination improved progression-free survival (PFS) in patients with BRCA1/2 hormone receptor-positive (HR+) or triple-negative breast cancer (TNBC), subgroup analysis of the phase III BROCADE3* trial showed.

High-dose IV iron cuts risk of classic MI in CKD

Elvira Manzano, 01 Jul 2020

Proactive treatment with high-dose intravenous (IV) iron reduces the risk for type 1 or classic myocardial infarction (MI), but not type 2 MI, in patients with chronic kidney disease (CKD) on dialysis, according to a prespecified secondary analysis of the PIVOTAL study.

Longer imatinib use confers survival benefit for GI stromal tumours

Audrey Abella, 30 Jun 2020

Three years of adjuvant imatinib treatment is superior in efficacy vs 1-year use in patients with gastrointestinal stromal tumours (GIST) at high risk of recurrence post-surgery, according to the secondary analysis of the SSGXVIII/AIO* trial.

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!